CA2518195C - Antitumor effect potentiator and antitumor agent - Google Patents

Antitumor effect potentiator and antitumor agent Download PDF

Info

Publication number
CA2518195C
CA2518195C CA002518195A CA2518195A CA2518195C CA 2518195 C CA2518195 C CA 2518195C CA 002518195 A CA002518195 A CA 002518195A CA 2518195 A CA2518195 A CA 2518195A CA 2518195 C CA2518195 C CA 2518195C
Authority
CA
Canada
Prior art keywords
antitumor
tegafur
gimeracil
amount
enhancing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002518195A
Other languages
English (en)
French (fr)
Other versions
CA2518195A1 (en
Inventor
Junji Uchida
Koyo Shudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of CA2518195A1 publication Critical patent/CA2518195A1/en
Application granted granted Critical
Publication of CA2518195C publication Critical patent/CA2518195C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002518195A 2003-03-14 2004-03-11 Antitumor effect potentiator and antitumor agent Expired - Fee Related CA2518195C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003070097 2003-03-14
JP2003-070097 2003-03-14
PCT/JP2004/003189 WO2004081012A1 (ja) 2003-03-14 2004-03-11 抗腫瘍効果増強剤及び抗腫瘍剤

Publications (2)

Publication Number Publication Date
CA2518195A1 CA2518195A1 (en) 2004-09-23
CA2518195C true CA2518195C (en) 2009-07-07

Family

ID=32984641

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002518195A Expired - Fee Related CA2518195C (en) 2003-03-14 2004-03-11 Antitumor effect potentiator and antitumor agent

Country Status (21)

Country Link
US (2) US9611227B2 (enExample)
EP (1) EP1604991B1 (enExample)
JP (1) JP4610481B2 (enExample)
KR (1) KR100812693B1 (enExample)
CN (2) CN101357134A (enExample)
AT (1) ATE408408T1 (enExample)
AU (1) AU2004220205B2 (enExample)
BR (1) BRPI0408372A (enExample)
CA (1) CA2518195C (enExample)
CY (1) CY1108395T1 (enExample)
DE (1) DE602004016636D1 (enExample)
DK (1) DK1604991T3 (enExample)
ES (1) ES2312978T3 (enExample)
MX (1) MXPA05009781A (enExample)
NZ (1) NZ542150A (enExample)
PL (1) PL1604991T3 (enExample)
PT (1) PT1604991E (enExample)
RU (1) RU2334517C2 (enExample)
SI (1) SI1604991T1 (enExample)
TW (1) TW200503720A (enExample)
WO (1) WO2004081012A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090137640A1 (en) * 2005-04-01 2009-05-28 Taiho Pharmaceutical Co.Ltd Potentiator for radiation therapy comprising pyridine derivative as active ingredient
EP1864683B1 (en) * 2005-04-01 2010-09-01 Taiho Pharmaceutical Co., Ltd. Radiotherapy enhancer
JPWO2007043531A1 (ja) * 2005-10-07 2009-04-16 セレスター・レキシコ・サイエンシズ株式会社 抗腫瘍剤及び放射線併用療法感受性診断用遺伝子マーカー並びにその利用
WO2009139085A1 (ja) * 2008-05-12 2009-11-19 静岡県 抗腫瘍剤、キット及び癌治療方法
JP5553522B2 (ja) * 2009-03-31 2014-07-16 大鵬薬品工業株式会社 経口投与用医薬組成物
JP5566376B2 (ja) * 2009-04-22 2014-08-06 大鵬薬品工業株式会社 腎細胞癌に対する化学療法の治療効果予測方法
CN102309491B (zh) * 2010-07-02 2015-06-10 天津金耀集团有限公司 一种替加氟、吉美斯特复方注射液
BR112013030093B1 (pt) * 2011-05-25 2019-12-10 Taiho Pharmaceutical Co Ltd comprimido revestido seco de desintegração oral contendo tegafur, gimeracilo e oteracilo potássico
EP3053578B1 (en) * 2013-09-30 2020-12-23 Taiho Pharmaceutical Co., Ltd. Combination cancer therapy using azabicyclo compound
CN106692173A (zh) * 2015-11-18 2017-05-24 北京诺普德医药科技有限公司 一种抗肿瘤复方组合物及其应用
CN106581001B (zh) * 2016-11-03 2018-12-21 江苏恒瑞医药股份有限公司 一种替吉奥组合物的制备方法
KR102258514B1 (ko) 2019-09-23 2021-05-31 연세대학교 산학협력단 신규한 다층형 좌약 제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0443028B1 (en) * 1989-01-05 1993-09-29 Otsuka Pharmaceutical Co., Ltd. Non-injection carcinostatic agent for suppressing occurrence of inflammation due to 5-fluorouracil and method for curing cancer
DE69121551T2 (de) * 1990-09-07 1997-01-02 Taiho Pharmaceutical Co Ltd Antineoplastisch wirkender und den antineoplastischen effekt verstärkender wirkstoff
KR0148589B1 (ko) * 1991-05-27 1998-11-02 고바야시 유끼오 항종양 효과의 상승 및 종양의 치료를 위한 조성물 및 키트
CH683262A5 (it) * 1992-01-22 1994-02-15 Applied Pharma Res Procedimento per la separazione dei diastereomeri del sale di calcio dell'acido (6(R,S)-N-formiltetraidrofolico).
WO2001066102A2 (en) * 2000-03-08 2001-09-13 Bristol-Myers Squibb Company Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
EP1368034A1 (en) 2001-03-06 2003-12-10 Bristol-Myers Squibb Company Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
JPWO2003004640A1 (ja) * 2001-07-05 2004-10-28 大鵬薬品工業株式会社 抗癌剤感受性測定用ｄｎａアレイ

Also Published As

Publication number Publication date
EP1604991B1 (en) 2008-09-17
DE602004016636D1 (de) 2008-10-30
CN101357134A (zh) 2009-02-04
JP4610481B2 (ja) 2011-01-12
DK1604991T3 (da) 2009-01-05
ATE408408T1 (de) 2008-10-15
RU2005131839A (ru) 2006-02-10
TW200503720A (en) 2005-02-01
US9611227B2 (en) 2017-04-04
NZ542150A (en) 2009-09-25
JPWO2004081012A1 (ja) 2006-06-08
AU2004220205A1 (en) 2004-09-23
KR100812693B1 (ko) 2008-03-13
MXPA05009781A (es) 2005-10-26
US20060116345A1 (en) 2006-06-01
TWI295173B (enExample) 2008-04-01
PT1604991E (pt) 2008-10-27
RU2334517C2 (ru) 2008-09-27
WO2004081012A1 (ja) 2004-09-23
KR20050106119A (ko) 2005-11-08
AU2004220205B2 (en) 2010-06-17
SI1604991T1 (sl) 2009-02-28
ES2312978T3 (es) 2009-03-01
EP1604991A1 (en) 2005-12-14
US20170157131A1 (en) 2017-06-08
BRPI0408372A (pt) 2006-03-21
CA2518195A1 (en) 2004-09-23
US9814724B2 (en) 2017-11-14
EP1604991A4 (en) 2006-05-03
PL1604991T3 (pl) 2009-02-27
CN1761665A (zh) 2006-04-19
CY1108395T1 (el) 2014-02-12

Similar Documents

Publication Publication Date Title
US9814724B2 (en) Antitumor effect potentiator and antitumor agent
JP2022501344A (ja) 新規キナゾリンｅｇｆｒ阻害剤
TWI426909B (zh) Radiation therapy enhancer
JP3208437B2 (ja) 癌転移抑制剤
JP2557303B2 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
US5534513A (en) Antitumor potentiator and antitumor composition
JPWO1992004028A1 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
AU2005251588B2 (en) Antitumor effect fortifier, antitumor agent and method of therapy for cancer
US8410096B2 (en) Antitumor agent, kit and method of treating cancer
HK1127546A (en) Antitumor effect potentiator and antitumor agent

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210311